このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ADBiotech マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Hong-Geo Jung

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	33.8%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some Debt

Sep 02

CEO（最高経営責任者

Hong-Geo Jung

no data

在職期間

Mr. Hong-Geo Jung is Chief Executive Officer of ADBiotech Co., Ltd.

ADBiotech マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021

Recent updates

New major risk - Share price stability

Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some Debt

New minor risk - Share price stability

ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd

Full year 2023 earnings released: ₩313 loss per share (vs ₩297 profit in FY 2022)

Investor sentiment improves as stock rises 20%

Investor sentiment deteriorates as stock falls 18%

New major risk - Share price stability

Investor sentiment improves as stock rises 19%

Third quarter 2023 earnings released: ₩104 loss per share (vs ₩29.00 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 35%

ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion.

ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in funding

ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding

ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021

New 90-day high: ₩26,700

New 90-day high: ₩22,950

New 90-day high: ₩20,000

New 90-day high: ₩19,950

New 90-day high: ₩19,000

New 90-day high - ₩16,900

ADBiotech Co., Ltd. announced that it has received KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.

ADBiotech Co., Ltd. announced that it expects to receive KRW 1 billion in funding

ADBiotech Co., Ltd. announced that it expects to receive KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.

CEO（最高経営責任者

在職期間

ADBiotech マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021

Recent updates

New major risk - Share price stability

Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some Debt

New minor risk - Share price stability

ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd

Full year 2023 earnings released: ₩313 loss per share (vs ₩297 profit in FY 2022)

Investor sentiment improves as stock rises 20%

Investor sentiment deteriorates as stock falls 18%

New major risk - Share price stability

Investor sentiment improves as stock rises 19%

Third quarter 2023 earnings released: ₩104 loss per share (vs ₩29.00 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 35%

ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion.

ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in funding

ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding

ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021

New 90-day high: ₩26,700

New 90-day high: ₩22,950

New 90-day high: ₩20,000

New 90-day high: ₩19,950

New 90-day high: ₩19,000

New 90-day high - ₩16,900

ADBiotech Co., Ltd. announced that it has received KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.

ADBiotech Co., Ltd. announced that it expects to receive KRW 1 billion in funding

ADBiotech Co., Ltd. announced that it expects to receive KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04